Latest News about Psychedelics Research
Recent news which mentions Psychedelics Research
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
From Benzinga
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
April 15, 2024
From Benzinga
From Benzinga
Psychedelics Reform Update: Missouri's $10M Budget, Maine's & Maryland's Study Groups, Oregon's Re-Crim And More
April 05, 2024
From Benzinga
From Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
From Benzinga
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
March 29, 2024
From Benzinga
From Benzinga
PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
March 27, 2024
Tickers
MDXXF
From Benzinga
From Benzinga
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
March 25, 2024
From Benzinga
Congress Discusses Remaining FY2024 Spending Bill With Provisions On Cannabis Sales And Psychedelic Clinical Trials
March 22, 2024
From Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
From Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
March 16, 2024
From Benzinga
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
From Benzinga
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
March 01, 2024
From Benzinga
Beckley Academy's Open-Source Psychedelic Therapy Learning Framework Is Out: What's It All About? Authoring Team Shares Insights
February 29, 2024
From Benzinga
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
February 28, 2024
From Benzinga
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000
January 31, 2024
From Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
From Benzinga
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
From Benzinga
DEA Acknowledges Psychedelics & Cannabis Research Needs, Seeks Production Increases
November 01, 2023
From Benzinga
Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents
October 26, 2023
From Benzinga
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
October 23, 2023
From Benzinga
Harvard's New Psychedelics Research Program Backed By Former Tesla Director's $16M Donation
October 18, 2023
From Benzinga
From Benzinga
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
September 15, 2023
Tickers
NUMIF
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free
Information
Copyright 2024. BUSINESS INSURANCE HOLDINGS
